Myers TR. Guidelines for asthma management: a review and comparison of 5 current guidelines. Respir Care. 2008;53(6):751–67.
Ernst P, Spitzer WO, Suissa S, et al. Risk of fatal and near-fatal asthma in relation to inhaled corticosteroid use. JAMA. 1992;268:3462–4.
Donahue JG, Weiss ST, Livingston JM, Goetsch MA, Greineder DK, Platt R. Inhaled steroids and the risk of hospitalization for asthma. JAMA. 1997;277:887–91.
Suissa S, Ernst P, Benayoun S, Baltzan M, Cai B. Low-dose inhaled corticosteroids and the prevention of death from asthma. N Eng J Med. 2000;343(5):332–6.
Rossi GA, Cerasoli F, Cazzola M. Safety of inhaled corticosteroids: room for improvement. Pulm Pharmacol Ther. 2007;20:23–5.
Dahl R. Systemic side effects of inhaled corticosteroids in patients with asthma. Respir Med. 2006;100(8):1307–17.
Expert panel report 3: guidelines for the diagnosis and management of asthma. Bethesda (MD): National Institutes of Health, National Asthma Education and Prevention Program; 2007. Publication No. 08-4051. http://www.nhlbi.nih.gov/health-pro/guidelines/current/asthma-guidelines/full-report. Accessed Oct 12 2016.
Bell MC, Busse WW. The Biology of Asthma. In: Grippi MA, Elias JA, Fishman JA, Kotloff RM, Pack AI, Senior RM, Siegel MD, editors. Fishman’s pulmonary diseases and disorders [Internet]. 5th ed. NYC: McGraw-Hill Education; 2015. http://accessmedicine.mhmedical.com.eres.library.manoa.hawaii.edu/content.aspx?bookid=1344&Sectionid=81188782. Accessed Sep 29 2016.
Johansson AK, Sergejeva S, Sjostrand M, Lee JJ, Lotvall J. Allergen-induced traffic of bone marrow eosinophils, neutrophils and lymphocytes to airways. Eur J Immunol. 2004;34:3135–45.
Busse WW, Lemanske RF. Asthma. N Engl J Med. 2001;344(5):350–62.
Stevenson DD, Szczeklik A. Clinical and pathologic perspectives on aspirin sensitivity and asthma. J Allergy Clin Immunol. 2006;118(4):773–86 (quiz 787-8, Epub 2006 Sep 1).
Holgate ST, Polosa R. The mechanisms, diagnosis, and management of severe asthma in adults. Lancet. 2006;368(9537):780–93.
Lemanski RF. Issues in understanding pediatric asthma: epidemiology and genetics. J Allergy Clin Immunol. 2002;109(6 Suppl):S521–4.
Barnes PJ. Review inhaled corticosteroids. Pharmaceuticals (Basel). 2010;3(3):514–40.
Dostert A, Heinzel T. Negative glucocorticoid receptor response elements and their role in glucocorticoid action. Curr Pharm Des. 2004;10:2807–16.
Mak JCW, Nishikawa M, Barnes PJ. Glucocorticoids increase β2-adrenergic receptor transcription in human lung. Am J Physiol. 1995;12:L41–6.
Baraniuk JN, Ali M, Brody D, et al. Glucocorticoids induce β2-adrenergic receptor function in human nasal mucosa. Am J Respir Crit Care Med. 1997;155:704–10.
Ito J, Ito M, Elliott WM, et al. Decreased histone deacetylase activity in chronic obstructive pulmonary disease. New Engl J Med. 2005;352:1967–76.
Hew M, Bhavsar P, Torrego A, et al. Relative corticosteroid insensitivity of peripheral blood mononuclear cells in severe asthma. Am J Respir Crit Care Med. 2006;174:134–41.
Barnes PJ. Role of HDAC2 in the pathophysiology of COPD. Ann Rev Physiol. 2009;71:451–64.
Derendorf H. Pharmacokinetic and pharmacodynamics properties of inhaled ciclesonide. J Clin Pharmacol. 2007;47(6):782–9.
Derendorf H, Nave R, Drollmann A, Cerasoli F, Wurst W. Relevance of pharmacokinetics and pharmacodynamics of inhaled corticosteroids to asthma. Eur Respir J. 2006;28(5):1042–50.
Hubner M, Hochhaus G, Derendorf H. Comparative pharmacology, bioavailability, pharmacokinetics, and pharmacodynamics of inhaled glucocorticosteroids. Immunol Allergy Clin N Am. 2005;25(3):469–88.
Kelly HW. Pharmaceutical characteristics that influence the clinical efficacy of inhaled corticosteroids. Ann Allergy Asthma Immunol. 2003;91:326–34.
Sobande PO, Kercsmar CM. Inhaled corticosteroids in asthma management. Respir Care. 2008;53(5):625–33.
Daley-Yates PT. Inhaled corticosteroids: potency, dose equivalence and therapeutic index. Br J Clin Pharmacol. 2015;80(3):372–80.
Kelly HW. Comparison of inhaled corticosteroids: an update. Annu Pharmacother. 2009;43(3):519–27.
Deeks ED, Perry CM. Ciclesonide: a review of its use in the management of asthma. Drugs. 2008;68:1741–70.
Sharpe M, Jarvis B. Inhaled mometasone furoate: a review of its use in adults and adolescents with persistent asthma. Drugs. 2001;61:1325–50.
Edsbacker S, Brattsand R. Budesonide fatty-acid esterification: a novel mechanism prolonging binding to airway tissue. Review of available data. Ann Allergy Asthma Immunol. 2002;88:609–16.
Miller-Larsson A, Mattsson H, Hjertberg E, Dahlback M, Tunek A, Brattsand R. Reversible fatty acid conjugation of budesonide. Novel mechanism for prolonged retention of topically applied steroid in airway tissue. Drug Metab Dispos. 1998;26:623–30.
Nave R, Meyer W, Fuhst R, Zech K. Formation of fatty acid conjugates of ciclesonide active metabolite in the rat lung after 4-week inhalation of ciclesonide. Pulm Pharmacol Ther. 2005;18:390–6.
Mukker JK, Singh RSP, Derendorf H. Ciclesonide: a pro-soft drug approach for mitigation of side effects of inhaled corticosteroids. J Pharm Sci. 2016;105:2509–14.
Szefler SJ, Martin RJ, King TS, et al. Significant variability in response to inhaled corticosteroids for persistent asthma. J Allergy Clin Immunol. 2002;109(3):410–8.
Wells KE, Peterson EL, Ahmedani BK, Williams LK. Real world effects of once vs. greater daily inhaled corticosteroid dosing on medication adherence. Ann Allergy Asthma Immunol. 2013;111(3):216–20.
Williams LK, Peterson EL, Wells K, et al. Quantifying the proportion of severe asthma exacerbations attributable to inhaled corticosteroid nonadherence. J Allergy Clin Immunol. 2011;128(6):1185–91.
Chauhan BF, Chartrand C, Ducharme FM. Intermittent versus daily inhaled corticosteroids for persistent asthma in children and adults. Cochrane Database Syst Rev. 2012:CD009611. doi:10.1002/14651858CD009611.pub2.
Dolovich MA, MacIntyre NR, Dhand R, Gross NJ, Hess, Pierson DJ. Consensus conference on aerosols and delivery devices. Respir Care. 2000;45:588–776.
Dekhuijzen PNR, Lavorini F, Usmani OS. Patients’ perspectives and preferences in the choice of inhalers: the case for Respimat® or HandiHaler®. Dovepress. 2016;10:1561–72.
Anderson P. Use of Respimat Soft Mist inhaler in COPD patients. Int J Chron Obstruct Pulmon Dis. 2006;1(3):251–9.
Lavorini F, Fontana GA, Usmani OS. New inhaler devices—the good, the bad and the ugly. Respiration. 2014;88(1):3–15.
Bousquet J, Ben-Joseph R, Messonnier M, Alemao E, Gould AL. A meta-analysis of the dose–response relationship of inhaled corticosteroids in adolescents and adults with mild to moderate persistent asthma. Clin Ther. 2002;24:1–20.
Dahl R, Lundback B, Malo JL, International Study Group, et al. A dose-ranging study of fluticasone propionate in adult patients with moderate asthma. Chest. 1993;104:1352–8.
Gaddie J, Reid IW, Skinner C, Petrie GR, Sinclair DJ, Palmer KN. Aerosol beclomethasone dipropionate: a dose–response study in chronic bronchial asthma. Lancet. 1973;ii:280–1.
Welch M, Bernstein D, Gross G, Kane RE, Banerji D, Azmacort HFA Study Group. A controlled trial of chlorofluorocarbon-free triamcinolone acetonide inhalation aerosol in the treatment of adult patients with persistent asthma. Chest. 1999;116:1304–12.
Kemp JP, Berkowitz RB, Miller SD, Murray JJ, Nolop K, Harrison JE. Mometasone furoate administered once daily is as effective as twice-daily administration for treatment of mild-to-moderate persistent asthma. J Allergy Clin Immunol. 2000;106:485–92.
Busse WW, Chervinsky P, Condemi J, et al. Budesonide delivered by Turbuhaler is effective in a dose-dependent fashion when used in the treatment of adult patients with chronic asthma. J Allergy Clin Immunol. 1998;101(4 Pt 1):457–63.
Currie GP, Fowler SJ, Lipworth BJ. Dose response of inhaled corticosteroids on bronchial hyperresponsiveness: a meta-analysis. Ann Allergy Asthma Immunol. 2003;90:194–8.
Gibson PG, Saltos N, Borgas T. Airway mast cells and eosinophils correlate with clinical severity and airway hyperresponsiveness in corticosteroid-treated asthma. J Allergy Clin Immunol. 2000;105:752–9.
Jatakanon A, Lim S, Chung KF, Barnes PJ. An inhaled steroid improves markers of airway inflammation in patients with mild asthma. Eur Respir J. 1998;12:1084–8.
Hojo M, Kudo K. Dose–response relationship for inhaled corticosteroids and the add-on effect of long-acting β2-adrenergic receptor agonists in adult chronic asthmatics. Allergol Int. 2004;43:291–9.
Pedersen S, O’Byrne P. A comparison of the efficacy and safety of inhaled corticosteroids in asthma. Allergy. 1997;52(Suppl):1–34.
Kelly HW. Potential adverse effects of the inhaled corticosteroids. J Allergy Clin Immunol. 2003;112:469–78.
Pauwels RA, Lofdahl CG, Postma DS, Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. N Engl J Med. 1997;337-1405-11.
Rank MA, Peters SP. The risks, benefits, and uncertainties of stepping down asthma medications. J Allergy Clin Immunol Pract. 2014;2(5):503–9.
Global Initiative for Asthma (GINA). Pocket guide for asthma management and prevention (for adults and children older than 5 years). Updated 2017. http://ginasthma.org/2017-pocket-guide-for-asthma-management-and-prevention/. Accessed April 4 2017.
Martinez FD, Chinchilli VM, Morgan WJ, et al. Use of beclomethasone dipropionate as rescue treatment for children with mild persistent asthma (TREXA): a randomized, double-blind, placebo-controlled trial. Lancet. 2011;377:650–7.
Juniper EF, Kline PA, Vanzieleghem MA, Hargreave FE. Reduction of budesonide after a year of increased use: a randomized controlled trial to evaluate whether improvements in airway responsiveness and clinical asthma are maintained. J Allergy Clin Immunol. 1991;87:483–9.
ZuWallack RL, Rosen JP, Cohen L, et al. The effectiveness of once-daily dosing of inhaled flunisolide in maintaining asthma control. J Allergy Clin Immunol. 1997;99:278–85.
Visser ML, Postma DS, Arends LR, de Vries TW, Duiverman EJ, Brand PL. One-year treatment with different dosing schedules of fluticasone propionate in childhood asthma. Am J Respir Crit Care Med. 2001;164:2073–7.
Hawkins G, McMahon AD, Twaddle S, Wood SF, Ford I, Thomson NC. Stepping down inhaled corticosteroids in asthma: a randomized controlled trial. BMJ. 2003;326:1115.
Papi A, Canonica GW, Maestrelli P, et al. Rescue use of beclomethasone and albuterol in a single inhaler for mild asthma. N Engl J Med. 2007;356:2040–52.
American Lung Association Asthma Clinical Research Network. Randomized comparison of strategies for reducing treatment in mild persistent asthma. N Engl J Med. 2007;356:2027–39.
Tonelli M, Bacci E, Dente FL, et al. Predictors of symptom recurrence after lose-dose inhaled corticosteroid cessation in mild persistent asthma. Respir Med. 2006;100:622–9.
Leuppi JD, Salome CM, Jenkins CR, Anderson SD, Xuan W, Marks GB, Koskela H, Brannan JD, Freed R, Andersson M, Chan HK, Woolcock AJ. Predictive markers of asthma exacerbation during stepwise dose reduction of inhaled corticosteroids. Am J Respir Crit Care Med. 2001;163:406–12.
Belda J, Parameswaran K, Lemiere C, Kamada D, O’Byrne PM, Hargreave FE. Predictors of loss of asthma control induced by corticosteroid withdrawal. Can Resp J. 2006;13:129–33.
Tsurikisawa N, Oshikata C, Tsuburai T, et al. Markers for step-down of inhaled corticosteroid therapy in adult asthmatics. Allergol Int. 2012;61:419–29.
Rank MA, Branda ME, McWilliams DB, et al. Outcomes of stepping down asthma medications in a guideline-based pediatric asthma management program. Ann Allergy Asthma Immunol. 2013;110:354–8.
Zacharasiewicz A, Wilson N, Lex C, et al. Clinical use of noninvasive measurements of airway inflammation in steroid reduction in children. Am J Respir Crit Care Med. 2005;171:1077–82.
Hoffmann HJ, Nielsen LP, Harving H, Heinig JH, Dahl R. Asthmatics able to step down from inhaled corticosteroid treatment without loss of asthma control have low serum eotaxin/CCL11. Clin Respir J. 2008;2:149–57.
Baba K, Sakakibara A, Yagi T, Niwa S, Wakayama H, Takagi K. Long-term observations of the clinical course after step down of corticosteroid inhalation therapy in adult chronic asthmatics: correlation with serum levels of eosinophil cationic protein. Respirology. 2002;7:255–66.
Jatakanon A, Lim S, Kharitonov SA, Chung KF, Barnes PJ. Correlation between exhaled nitric oxide, sputum eosinophils, and methacholine responsiveness in patients with mild asthma. Thorax. 1998;53:91–5.
Berlyne GS, Parameswaran K, Kamada D, Efthimiadis A, Hargreave FE. A comparison of exhaled nitric oxide and induced sputum as markers of airway inflammation. J Allergy Clin Immunol. 2000;106:638–44.
Mehta V, Stokes JR, Berro A, Romero FA, Casale TB. Time-dependent effects of inhaled corticosteroids on lung function, bronchial hyperresponsiveness, and airway inflammation in asthma. Ann Allergy Asthma Immunol. 2009;103:31–7.
Smith AD, Cowan JO, Brassett KP, Herbison GP, Taylor DR. Use of exhaled nitric oxide measurements to guide treatment in chronic asthma. N Engl J Med. 2005;352:2163–73.
Greening AP, Ind PW, Northfield M, Shaw G, Allen & Hanburys Limited UK Study Group. Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Lancet. 1994;344:219–24.
Shrewsbury S, Pyke S, Britton M. Meta-analysis of increased dose of inhaled steroid or addition of salmeterol in symptomatic asthma (MIASMA). BMJ. 2000;320:1368–73.
Peters SP, Bleecker ER, Canonica GW, et al. Serious asthma events with budesonide plus formoterol vs. budesonide alone. N Engl J Med. 2016;375(9):850–60.
Stempel DA, Raphiou IH, Kral KM, et al. Serious asthma events with fluticasone plus salmeterol versus fluticasone alone. N Engl J Med. 2016;374(19):1822–30.
Castle W, Fuller R, Hall J, Palmer J. Serevent Nationwide Surveillance Study: comparison of salmeterol with salbutamol in asthmatic patients who require regular bronchodilator treatment. BMJ. 1993;306:1034–7.
Nelson HS, Weiss ST, Bleecker ER, Yancey SW, Dorinsky PM. The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest. 2006;129:15–26.
Bateman ED, Boushey HA, Bousquet J, Busse WW, Clark TJH, et al. Can guideline-defined asthma control be achieved? The gaining optimal asthma control study. Am J Respir Crit Care Med. 2004;170:836–44.
O’Byrne PM, Barnes PJ, Rodriguez-Roisin R, et al. Low dose inhaled budesonide and formoterol in mild persistent asthma: the OPTIMA randomized trial. Am J Respir Crit Care Med. 2001;164(8 Pt 1):1392–7.
O’Byrne PM, Bisgaard H, Godard PP, et al. Budesonide/formoterol combination therapy as both maintenance and reliever medication in asthma. Am J Respir Crit Care Med. 2005;171:129–36.
Rabe KF, Pizzichini E, Stallberg B, et al. Budesonide/formoterol in a single inhaler for maintenance and relief in mild-to-moderate asthma: a randomized, double-blind trial. Chest. 2006;129:246–56.
Scicchitano R, Aalbers R, Ukena D, et al. Efficacy and safety of budesonide/formoterol single inhaler therapy versus a higher dose of budesonide in moderate to severe asthma. Curr Med Res Opin. 2004;20:1403–18.
Lambrecht BN, Hammad H. The immunology of asthma. Nat Immunol. 2015;16:45–56.
US Food and Drug Administration. FDA drug safety communication: new safety requirements for long-acting inhaled asthma medications called long-acting beta-agonists (LABAs); 2010. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm200776.htm. Accessed on April 4 2017.
Mori K, Fujisawa T, Inui N, et al. Step-down treatment from medium-dosage of budesonide/formoterol in controlled asthma. Respir Med. 2016;119:1–6.
Bozek JL, Kraft M, Krishnan JA, et al. Long-acting beta-agonist step-off in patients with controlled asthma. Arch Intern Med. 2012;172(18):1365–75.
Allen DB, Leonard B, Hartmut D, Robert D, Gene LC, Szefler SJ. Inhaled corticosteroids: past lessons and future issues. J Allergy Clin Immunol. 2003;112(3 Suppl):S1–40.
Brutsche MH, Brutsche IC, Munawar M, et al. Comparison of pharmacokinetics and systemic effects of inhaled fluticasone propionate in patients with asthma and healthy volunteers: a randomized crossover study. Lancet. 2000;356:556–61.
Weiner P, Berar-Yanay N, Davidovich A, Magadle R. Nocturnal cortisol secretion in asthmatic patients after inhalation of fluticasone propionate. Chest. 1999;116:931–4.
Pedersen S, O’Byrne P. A comparison of the efficacy and safety of inhaled corticosteroids in asthma. Allergy. 1997;52(Suppl 39):1–34.
Salvatoni A, Piantanida E, Nosetti L, Nespoli L. Inhaled corticosteroids in childhood asthma: long-term effects on growth and adrenocortical function. Paediatr Drugs. 2003;5:351–61.
Meibohm B, Hochhaus G, Rohatagi S, et al. Dependency of cortisol suppression on the administration time of inhaled corticosteroids [published correction appears in J Clin Pharmacol. 1997;37:1000]. J Clin Pharmacol. 1997;37:704–10.
Barnes NC. Safety of high-dose inhaled corticosteroids. Respir Med. 1993;87(Suppl A):27–31.
Todd GR, Acerini CL, Ross-Russell R, Zahra S, Warner JT, McCance D. Survey of adrenal crisis associated with inhaled corticosteroids in the UK. Arch Dis Child. 2002;87:457–61.
Martin RJ, Szefler SJ, Chinchilli VM, et al. Systemic effect comparisons of six inhaled corticosteroid preparations. Am J Respir Crit Care Med. 2002;165(10):1377–83.
Lipworth BJ. Systemic adverse effects of inhaled corticosteroid therapy: a systemic review and meta-analysis. Arch Intern Med. 1999;159:941–55.
Wolthers OB, Hansen M, Juul A, Nielsen NK, Pedersen S. Knemometry, urine cortisol excretion, and measures of the insulin-like growth factor axis and collagen turnover in children treated with inhaled glucocorticosteroids. Pediatr Res. 1997;41:44–50.
Kannisto S, Korppi M, Remes K, Voutilainen R. Adrenal suppression, evaluated by a low dose adrenocorticotropin test, and growth in asthmatic children treated with inhaled steroids. J Clin Endocrinol Metab. 2000;85:652–7.
Barnes NC, Hallett C, Harris TA. Clinical experience with fluticasone propionate in asthma: a meta-analysis of efficacy and systemic activity compared with budesonide and beclomethasone dipropionate at half the microgram dose or less. Respir Med. 1998;92:95–104.
The Childhood Asthma Management Program. (CAMP) Research Group. Long-term effects of budesonide or nedocromil in children with asthma. N Engl J Med. 2000;343:1054–63.
Silverstein MD, Yunginger JW, Reed CE, et al. Attained adult height after childhood asthma: effect of glucocorticoid therapy. J Allergy Clin Immunol. 1997;99:466–74.
Agertoft L, Pedersen S. Effect of long-term treatment with inhaled budesonide on adult height in children with asthma. N Engl J Med. 2000;343:1064–9.
Guilbert TW, Morgan WJ, Krawiec M, et al. The Prevention of Early Asthma in Kids study: design, rationale and methods for the Childhood Asthma Research and Education Network. Control Clin Trials. 2004;25(3):286–310.
Loke YK, Blanco P, Thavarajah M, Wilson AM. Impact of inhaled corticosteroids on growth in children with asthma: systematic review and meta-analysis. PLoS One. 2015;10(7):e0133428. doi:10.1371/journal.pone.0133428.
Kelly WH, Sternberg AL, Lescher R, et al. Effect of inhaled glucocorticoids in childhood on adult height. NEJM. 2012;367:904–12.
Hopp RJ, Degan JA, Phelan J, Lappe J, Gallagher GC. Cross-sectional study of bone density in asthmatic children. Pediatr Pulmonol. 1995;20:189–92.
Gregson RK, Rao R, Murrills AJ, Taylor PA, Warner JO. Effect of inhaled corticosteroids on bone mineral density in childhood asthma: comparison of fluticasone propionate with beclomethasone dipropionate. Osteoporos Int. 1998;8:418–22.
Schlienger RG, Jick SS, Meier CR. Inhaled corticosteroids and the risk of fractures in children and adolescents. Pediatrics. 2004;114(2):469–73.
Monadi M, Javadian Y, Cheraghi M, Heidari B, Amiri M. Impact of treatment with inhaled corticosteroids on bone mineral density of patients with asthma: related with age. Osteoporos Int. 2015;262:2013–8.
Richy F, Bousquet J, Ehrlich GE, et al. Inhaled corticosteroids effects on bone in asthmatic and COPD patients: a quantitative systematic review. Osteoporos Int. 2003;14(3):179–90 (Epub).
Laatikainen AK, Kroger HP, Tukiainen HO, Honkanen RJ, Saarikoski SV. Bone mineral density in perimenopausal women with asthma: a population-based cross-sectional study. Am J Respir Crit Care Med. 1999;159(4 Pt 1):1179–85.
Ip M, Lam K, Yam L, Kung A, Ng M. Decreased bone mineral density in premenopausal asthma patients receiving long-term inhaled steroids. Chest. 1994;105(6):1722–7.
Jung JW, Kang HR, Kim JY, Lee SH, Kim SS, Cho SH. Are asthmatic patients prone to bone loss? Ann Allergy Asthma Immunol. 2014;112(5):426–31. doi:10.1016/j.anai.2014.02.013.
Wong CA, Walsh LJ, Smith CJP, Wisniewski AF, Lewis SA, Hubbard R, et al. Inhaled corticosteroid use and bone mineral density in patients with asthma. Lancet. 2000;355:1399–403.
Matsumoto H, Ishihara K, Hasegawa T, Umeda B, Niimi A, Hino M. Effects of inhaled corticosteroid and short courses of oral corticosteroids on bone mineral density in asthmatic patients: a 4-year longitudinal study. Chest. 2001;120(5):1468–73.
Wheelock C, St Anna L. Clinical inquiry. Do inhaled steroids reduce bone mineral density and increase fracture risk? J Fam Pract. 2012;61(8):493–508.
Tattersfield AE, Town GI, Johnell O, et al. Bone mineral density in subjects with mild asthma randomized to treatment inhaled corticosteroids or non-corticosteroid treatment for two years. Thorax. 2001;56(4):272–8.
Jones A, Fay JK, Burr M, Stone M, Hood K, Roberts G. Inhaled corticosteroid effects on bone metabolism in asthma and mild chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2002;1:CD003537.
Welch MJ. Inhaled steroids and severe viral infections. J Asthma. 1994;31:43–50.
Bahceciler NN, Nuhoglu Y, Nursoy MA, Kodalli N, Barlan IB, Basaran MM. Inhaled corticosteroid therapy is safe in tuberculin-positive asthmatic children. Pediatr Infect Dis J. 2000;19:215–8.
Singh S, Amin AV, Loke YK. Long-term use of inhaled corticosteroids and the risk of pneumonia in chronic obstructive pulmonary disease: a meta-analysis. Arch Intern Med. 2009;169:219–29.
Singh S, Loke YK. An overview of the benefits and drawbacks of inhaled corticosteroids in chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2010;5:189–95.
Suissa S, Patenaude V, Lapi F, Ernst P. Inhaled corticosteroids in COPD and the risk of serious pneumonia. Thorax. 2013;68:1029–36.
Eurich DT, Lee C, Marrie TJ, Majumdar SR. Inhaled corticosteroids and risk of recurrent pneumonia: a population-based, nested case-control study. Clin Infect Dis. 2013;57:1138–44.
McKeever T, Harrison TW, Hubbard R, Shaw D. Inhaled corticosteroids and the risk of pneumonia in people with asthma: a case–control study. Chest. 2013;144:1788–94.
Weatherall M, James K, Clay J, et al. Dose–response relationship for risk of non-vertebral fracture with inhaled corticosteroids. Clin Exp Allergy. 2008;38:1451–8.
Garbe E, LeLorier J, Boivin JF, Suissa S. Inhaled and nasal glucocorticoids and the risk of ocular hypertension or open-angle glaucoma. JAMA. 1997;277:722–7.
Samily N, Walton DS, Dreyer EB. Inhaled steroids: effect on intraocular pressure in patients without glaucoma. Can J Ophthalmol. 1996;31(3):120–3.
Pelkonen A, Kari O, Selroos O, Nikander K, Haahtela T, Turpeinen M. Ophthalmologic findings in children with asthma receiving inhaled budesonide. J Allergy Clin Immunol. 2008;122(4):832–4.
Capewell S, Reynolds S, Shuttleworth D, Edwards C, Finlay AY. Purpura and dermal thinning associated with high dose inhaled corticosteroids. BMJ. 1990;300:1548–51.
Mak VHF, Melchor R, Spiro SG. Easy bruising as a side-effect of inhaled corticosteroids. Eur Resp J. 1992;5:1066–74.
Roy A, Leblanc C, Paquette L, Ghezzo H, Cote J, Cartier A, et al. Skin bruising in asthmatic subjects treated with high doses of inhaled steroids: frequency an association with adrenal function. Eur Respir J. 1996;9:226–31.
Autio P, Karjalainen J, Risteli L, Kiistala U, Oikarinen A. Effects of an inhaled steroid (budesonide) on skin collagen synthesis of asthma patients in vivo. Am J Respir Crit Care Med. 1996;153:1172–5.
Pauwels RA, Lofdahl CG, Laitinen LA, et al. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease. N Engl J Med. 1999;340:1948–53.
Tashkin DP, Murray HE, Skeans M, Murray RP. Skin manifestations of inhaled corticosteroids in COPD patients: results from Lung Health Study II. Chest. 2004;126:1123–33.
Daley-Yates PT. Pharmacological aspects of glucocorticoid therapy. In: Wolthers OD, editor. Exogenous glucocorticoids in paediatric asthma. Kerala: Transworld Research Network; 2007. p. 1–18.
Daley-Yates PT, Harker AJ, Taylor S, Daniel MJ. Plasma protein binding of inhaled corticosteroids: reappraisal of its significance in systemic pharmacological activity. J Allergy Clin Immunol. 2005;115:S4.
Wolthers OD, Daley-Yates PT. Exogenous glucocorticoids in Paediatric asthma. In: Wolthers OD, editor. Inhaled glucocorticoids and hypothalamic–pituitary–adrenal axis function. Kerala: Transworld Research Network; 2007. p. 19–34.
Daley-Yates PT, Pierre LN. A physiologically based pharmacokinetic/pharmacodynamic model predicting cortisol suppression for inhaled corticosteroids. Am J Respir Crit Care Med. 2001;163:A518.
Crim C, Pierre LN, Daley-Yates PT. A review of the pharmacology and pharmacokinetics of fluticasone propionate and mometosone furoate. Clin Ther. 2001;23:1339–54.
Daley-Yates PT, Derks MGM, Weeks AT, Mehta RS, Beerahee M, Sousa A. Pharmacokinetics and pharmacodynamics of fluticasone propionate and mometasone furoate dry powder inhalers in healthy and asthmatic subjects. Am J Respir Crit Care Med. 2005;2:A354.
Allen A. The relationship between fluticasone furoate systemic exposure and cortisol suppression. Clin Pharmacokinet. 2013;52:885–96.
Hogger P, Rohdewald P. Glucocorticoid receptors and fluticasone propionate. Rev Contemp Pharmacother. 1998;9:501–22.
Daley-Yates PT, Kunka RL, Shen YY, Andrews SM, Callejas S, Ng C. Bioavailability of fluticasone propionate and mometasone furoate aqueous nasal sprays. Eur J Clin Pharmacol. 2004;60:265–8.
Falcoz C, Oliver R, McDowall J, Ventresca GP, Bye A, Daley-Yates PT. Bioavailability of orally administered micronised fluticasone propionate. Clin Pharmacokinet. 2000;39(Suppl. 1):9–15.
Taylor S, Harker A. Modification of the ultrafiltration technique to overcome solubility and non-specific binding challenges associated with the measurement of plasma protein binding of corticosteroids. J Pharm Biomed Anal. 2006;41:299–303.
Derendorf H, Hochhaus G, Meibohm B, Mollmann H, Bart J. Pharmacokinetics and pharmacodynamics of inhaled corticosteroids. J Allergy Clin Immunol. 1998;101:S440–6.
Kaliner MA. Pharmacologic characteristics and adrenal suppression with newer inhaled corticosteroids: a comparison of ciclesonide and fluticasone propionate. Clin Ther. 2006;28:319–31.
Mager DE, Jusko WJ. Quantitative structure–pharmacokinetic/pharmacodynamic relationships of corticosteroids in man. J Pharm Sci. 2001;91:2442–51.
Agertoft L, Pedersen S. Lung deposition and systemic bioavailability of fluticasone Diskus and budesonide Turbuhaler. Am J Respir Crit Care Med. 2003;168:779–82.
Mackie AE, McDowall JE, Falcoz C, Ventresca GP, Bye A, Daley-Yates PT. Pharmacokinetics of fluticasone propionate inhaled via the Diskhaler and Diskus powder devices in healthy subjects. Clin Pharmacokinet. 2000;39(1):23–30.
Thorsson L, Edsbacker S, Conradson TB. Lung deposition from Turbuhaler is twice that from a pressurised metered dose inhaler P-MDI. Eur Respir J. 1994;7:1839–44.
Agertoft L, Andersen A, Weibull E, Pedersen S. Systemic availability and pharmacokinetics of nebulized budesonide in pre-school children with asthma. Arch Dis Child. 1999;80:241–7.
Jeal W, Faulds D. Triamcinolone acetonide. A review of its pharmacological properties and therapeutic efficacy in the management of allergic rhinitis. Drugs. 1997;53:257–80.
Derendorf H, Hochhaus G, Rohatagi S, Möllmann H, Barth J, Sourgens H, Erdmann M. Pharmacokinetics of triamcinolone acetonide after intravenous, oral, and inhaled administration. J Clin Pharmacol. 1995;35:302–5.
Barth J, Damoiseaux M, Möllmann H, Brandis KH, Hochhaus G, Derendorf H. Pharmacokinetics and pharmacodynamics of prednisolone after intravenous and oral administration. Int J Clin Pharmacol Ther Toxicol. 1992;30:317–24.
Kelly HW. Comparison of inhaled corticosteroids. Ann Pharmacother. 1998;32:220–32. doi:10.1345/aph.17014.
Winkler J, Hochhaus G, Derendorf H. How the lung handles drugs: pharmacokinetics and pharmacodynamics of inhaled corticosteroids. Proc Am Thorac Soc. 2004;1:356–63.
Hübner M, Hochhaus G, Derendorf H. Comparative pharmacology, bioavailability, pharmacokinetics, and pharmacodynamics of inhaled glucocorticosteroids. Immunol Allergy Clin N Am. 2005;25:469–88.
Derendorf H, Nave R, Drollman A, Cerasoli F, Wurst W. Relevance of pharmacokinetics and pharmacodynamics of inhaled corticosteroids to asthma. Eur Respir J. 2006;28:1042–50.